⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIIB News
Biogen Inc. Common Stock
Leqembi included in China's commercial insurance innovative drug list USA - English USA - English
prnewswire.com
BIIB
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AMGN
PFE
LLY
AZN
BMY
NVS
SNY
GSK
UCB
ARQT
REGN
INCY
ABBV
BIIB
MRK
JNJ
VNDA
RAPT
CHAI
ONON
ION
ASMB
CRVS
APG
KSCP
KYMR
XBI
IBB
ADSK
CDNS
SNPS
John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), to Deliver Keynote Address on the Future of Biotech and Rare Disease Innovation at the 2026 MDA Clinical & Scientific Conference
globenewswire.com
AMGN
REGN
GILD
BMY
AZN
NVS
ARGX
BIIB
BBIO
SRRK
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
businesswire.com
STOK
BIIB
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
globenewswire.com
BIIB
STOK
Companion Diagnostics Market Research 2025: $21+ Bn Opportunities, Growth Drivers, Industry Trend Analysis, and Forecasts 2024-2034
globenewswire.com
PFE
MRK
AZN
TMO
ABT
AMGN
JNJ
BMY
LLY
MYGN
GRDX
BIIB
BDX
Vertero Appoints Jeffrey Kasten as Chief Business Officer
globenewswire.com
BIIB
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
globenewswire.com
BIIB
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
prnewswire.com
BIIB
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight
prnewswire.com
NVO
ULTX
SGMO
PFE
BMN
SNY
CHGC
RHHBY
ALNY
BIIB
BAY
TSEM
CSL
HEMA
LFB
OCT
SOBI
ASC